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Chronic fatigue syndrome and quality of life
Deb Roberts
Liverpool CFS Therapy Service, Royal 
Liverpool and Broadgreen University 
Hospitals, Liverpool, UK
Abstract: Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), 
is a challenging long-term condition (LTC) with complex and fluctuating symptoms. It is het-
erogeneous in presentation without diagnostic indicators; therefore, in health care encounters, 
insight must be gained from the patient’s perspective. One indicator of impact can be gained 
by measuring quality of life (QoL). By applying a patient-reported outcome measure (PROM), 
professionals can gather insights with direct relevance to the patient questioned. Such a tool 
can act therapeutically tool to promote holistic and individualized professional interventions 
and interval measurement can inform commissioning of specialist services. Standard practice 
appears not fully to capture the experience of CFS, while a search of the literature turned up 
QoL patient-reported outcome tools, but failed to reveal a CFS/ME-specific measure. The author 
explores a valid and reliable PROM that can monitor change and evaluate the UK National 
Institute of Clinical Excellence rehabilitation program, as delivered by specialist National 
Health Service units. An alternative, the World Health Organization’s quality-of life instrument 
(WHOQoL)-Bref26, is reviewed for relevance to the condition, measuring treatment outcomes 
and the wider debate of measuring QoL in LTCs.
Keywords: long-term conditions, patient perspective, assessment, quality of life, measurement
Introduction
Background
Approximately 15.4 million of the population in England report a long-term condition 
(LTC).1,2 Monitoring patients’ level of disability by assessing overall effect on quality 
of life (QoL) is regarded as essential by the author.3 A 2010 white paper4 emphasized 
the ability of patient-reported outcome measures (PROMs) to enhance LTC manage-
ment, not to be confused with satisfaction surveys.5 Nevertheless, the Medical Research 
Council6 and Reuben and Tinetti7 intimate that general tools may inadequately reflect 
experiences or the outcome of intervention in many LTCs. The author observes that 
despite best professional efforts, gaining a measurable understanding of the effect of 
chronic fatigue syndrome (CFS) and demonstrating the effectiveness of interventions 
can be considered problematic.8,9 PROMs are developing into a versatile interven-
tion that provides a rich data set and acts as a quality-improvement tool.9 However, 
measures need to be sensitive enough to capture complex variables and the impact of 
comorbidities10 and to inform clinical commissioning.11
The UK National Institute of Health and Care Excellence (NICE) CFS program 
delivered by specialist services promotes accurate diagnosis and practical recom-
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mendations that emphasize working in partnership, taking 
account of needs and preferences. An overview of strategies 
is offered in this article in relation to what the author is seek-
ing to measure. Managing both the physical and emotional 
components of the condition with an individualized approach 
includes cognitive behavioral and (for some) graded exercise 
approaches. NHS tertiary services, along with many other 
specialties, do not form part of The UK National Clini-
cal Audit and Patient Outcomes Programme.12,13 However, 
intensive users of the expensive health care services, the 
author is aware of the urgency to positively influence the 
LTC-reporting agenda and CFS specifically.14,15 This review 
seeks to explore a valid and reliable care measure that cap-
tures QoL, monitors change, and evaluates practice.
The condition
CFS, also known as myalgic encephalomyelitis (ME), is 
an LTC with significant and unpredictable symptoms and 
uncertain duration.6 Often referred to as ME/CFS in leading 
literature, new descriptors are under discussion.16 However, 
the NICE guidelines descriptor of CFS/ME will be the term 
applied in this article. As CFS/ME is heterogeneous in nature 
and without medical or diagnostic markers, those with the ill-
ness are frequently disbelieved, despite the dramatic changes 
to functional abilities and emotional well-being.17 GPs are 
likely to have up to 40 patients experiencing symptoms, and 
upward of 50% will need input from specialist services.18 
The author agrees with Reynolds et al,19 who emphasized 
the extensive burden of CFS/ME symptoms that require 
robust initiatives and without which prognosis is poor. The 
UK NICE guideline estimates a minimum prevalence in 
primary care of 0.2%,6 although a unified case definition or 
etiology is yet to achieve consensus.20 Despite fierce debate, 
there is a suggestion that physiological, neurological, and/
or autoimmune dysfunction combine to produce devastating 
physical, emotional, social, and economic consequences.21
Prior to the development of symptoms, patients most 
frequently report severe illness, surgery, accident, and/or 
physical and psychological or emotional trauma.22 Evidence 
exists that under the influence of such triggers, the condition 
begins with circadian rhythm dysregulation.23 A debilitating 
fatigue that is unlike everyday tiredness and not resolved by 
sleep or rest is reported, along with difficulties in memory 
and concentration.24 The developing sleep disorder results 
in daytime sleep, and the enforced rest rapidly develops into 
severe muscle deconditioning.25 Often described as the “pay-
back phenomenon”, patients recount an increase in symptoms 
of myalgia, dizziness, and tachycardia.26 Although not fully 
understood, symptoms including nausea, muscle tension, 
and disruption to bowel and bladder function also occur. It 
appears that the autonomic nervous system and fight-or-flight 
response are more greatly activated as patients attempt to 
maintain their previous functional lifestyle and responsi-
bilities levels.26 Sufferers experience a downward spiral of 
physical symptoms that can result in reactive anxiety and 
depression.27,28 Fenouillet et al29 confirms that pathogenesis 
appeare to be multifactorial.30
Current practice
The minimum data set (MDS) of PROMs agreed upon by 
the British Association of CFS/ME Professionals (BACME)7 
utilizes well-recognized and validated measures (Table 1). 
Fatigue, sleep, and self-efficacy are reviewed in a well-repli-
cated format, although the questions are general in nature.31–33 
Pain is represented by a visual analog scale.34 Many very 
specific but perhaps not entirely relevant physical activity 
descriptors are captured with the Short Form (SF)-36 – physi-
cal function scale,35 and mood through the Hospital Anxiety 
and Depression Scale (HADS).36 In common with other CFS 
specialists, the author suggests that HADS can confuse mood 
change with the results of fatigue. A narrow exploration of 
QoL is included through the EuroQol (EQ)-5D,37 the Clinical 
Global Improvement scale rating overall change at discharge 
when the MDS is repeated.38 The emphasis has been to assess 
Table 1 Questionnaires
Description
Chalder Fatigue 
Questionnaire31
Ten questions designed to describe difficulties 
with fatigue and associated symptoms, with four 
scored categories ranging from 0 (less than) to 
3 (much more than)
Epworth 
Sleepiness Scale32
Eight activity inquiries and likelihood of sleeping: 
0 (never) to 3 (high chance of dozing)
Self-Efficacy 
Scale for Chronic 
Illness33
Six inquiries beginning “How confident are you 
. . .” managing fatigue, physical, emotional/other 
symptoms, tasks, and other on a 10-point scale: 
1 (not confident) to 10 (completely confident)
Visual Analog 
Scale – pain34
Measured 0–100%
Short Form 3635 Ten questions about physical activity, with three 
responses: 1 (limited a lot), 2 (a little), or 3 (not 
at all)
Hospital Anxiety 
and Depression 
Scale36
Mood measure with seven questions for anxiety 
and seven for depression; four score responses: 
0 (no impact) to 3 (frequently affected)
European Quality 
of Life Measure37
Five questions on mobility, self-care, activity, 
pain, and mood in three categories: 1 (no 
problems) to 3 (extremely disabling) difficulties
Clinical Global 
Impression38
Seven questions, with responses ranging from 1 
(very much better) to 7 (very much worse)
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changes in physical function and ensure mood is monitored 
within specialist care.12
However, the author finds the prescribed questionnaires 
time-consuming, with limited suitability as therapeutic tools. 
The measures do not explore social, leisure, or work domains 
to any degree, neglecting intimacy and a more detailed QoL 
assessment. The complexity of scoring and the national 
database design for CFS/ME PROMs results requires expert 
interpretation, which is no longer feasible to provide. As 
qualitative analysis reveals ambiguities and fails to capture 
patient representation, the ability to report successful out-
comes to influence the planning and commissioning of local 
health care services may prove inadequate.39
What are we trying to measure?
Endorsed by the NHS Outcomes Framework,40 measuring 
what is important to the patient is regarded as the most 
therapeutic approach. Along with practitioners in LTC 
management, CFS/ME specialists are seeking insight into 
symptoms and impact of the condition on function, health 
behavior, and capacity to self-manage.41 Devlin and Appleby42 
observed that self-assessment of health and health-related 
QoL informed patient decision-making regarding treatment 
and lifestyle choices. There is increasing recognition of the 
need to understand personal experience of illness and patient 
needs better to foster shared decision-making.42 As Wearden 
et al43 confirmed, CFS/ME continues to be a diagnosis of 
exclusion through the fulfillment of symptom criteria without 
a clinical diagnostic test.12 Though not discussed in this paper, 
Fukuda et al24 offered frequently applied criteria for diagnosis 
and to support research into the condition. NICE12 go further, 
emphasizing the prerequisite of symptoms of fatigue and 
postexertion malaise, without which the condition cannot be 
confirmed. Difficulties remain, with many models offering 
elucidation and treatment options, but what is regarded as 
recovery remains contested.44
The most researched and endorsed treatment approaches 
currently include lifestyle and physical regimes and psycho-
logical therapies.45–48 Acknowledging and understanding the 
source of symptoms such as fatigue, pain, anxiety, and low 
mood is promoted by NICE.8 Sleep hygiene, the concept of 
pacing activity with rest,41 physical reconditioning, and a 
realistic return to commitments is addressed through grading 
and for some exercise.8,49 However, tackling the resulting loss 
and managing stress are also addressed. Examining one’s 
own and others’ expectations and workplace pressures are 
complemented with relaxation techniques and lifestyle goal 
setting.49 Health professionals practicing in CFS/ME reha-
bilitation have observed that positive change also requires 
a degree of acceptance and rediscovering meaning in life, 
despite the lack of full understanding of the mechanics of 
the condition.50,51 What practitioners are aiming for initially 
is stability.12 Pemberton and Cox26 point out that patients’ 
traumatic experiences and personality style are also ele-
ments to address in therapeutic encounters. Nelson et al41 
highlight the positive impacts of building confidence and 
resilience with relapse-prevention skills that prevent setbacks 
and protect health and well-being.51 In order to fully capture 
specialist treatment, Jason et al20 stress the importance of 
a comprehensive self-reporting tool to support assessment 
of biopsychosocial symptomatology, impact, and specialist 
interventions.
Devlin and Appleby42 confirm measuring and benchmark-
ing the performance of health care providers is necessary 
for patient safety, but Nelson et al warn an emphasis on 
measuring patient experiences must not misdirect the focus 
of therapy or become practitioner priorities.41 The application 
of PROMs in everyday practice has the potential to narrow 
the gap between practitioners’ and patients’ views of clinical 
reality and help tailor treatment plans to meet preferences 
applicable to CFS/ME and LTCs in general. Nelson et al41 
further observed that without the application of PROMs, 
health professionals’ understanding of the effect of complex 
disease and interventions is insufficient.
Literature review
Material was accessed through Ebsco’s electronic library 
search engine, employing Boolean operators to refine logical 
relationships among terms. CINAHL Complete, Information 
Science and Technology, Medline, PsycArticles, and PsycInfo 
databases were retrieved. Scopus (through SciVerse), the 
Cochrane Library, PubMed, and Web of Science were also 
reviewed, with closely overlapping results. The content of 
prominent journals similarly informed appraisal by highlight-
ing both historic and recent development drivers and clinical 
and political interest in the subject. A starting year of 1990 
was chosen to coincide with the growth in PROM develop-
ment. Those outside Europe, Australia, and North America 
were excluded, due to lack of familiarity or availability. The 
literature review sought to gather the most widely replicated 
and validated measures in studies most closely resembling the 
project setting. Results were very widely ranging, but selected 
as relating to adults with a diagnosis of CFS/ME as per the 
Fukuda criteria, which despite its potential shortcomings is 
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the most frequently applied diagnostic guide.24 Findings were 
scrutinized for their ability to provide meaningful direction.52
The search revealed an absence of uniform insights and a 
wide variety of interventions.53–56 Also sought was evidence 
of research into the application of PROMs for CFS/ME. 
CFS-specific measures proved to be few and not consistently 
evaluated.57 Devlin and Appleby42 observed that the sheer 
number of clinical measures made a comparison of health 
impacts problematic, and the author found that the PROMs 
utilized in prominent UK-based CFS/ME research generally 
measured the efficacy of cognitive, behavioral, and graded 
exercise therapies. The most consistently applied question-
naires were the Chalder Fatigue Questionnaire,31 full SF36,35 
HADS,36 and the Clinical Global Impression scale.38 With 
such reputable and consistently reproducible findings, these 
results have been influential in formulating NICE guidelines 
and continue to inform NHS tertiary care.12,25,43,58 Neverthe-
less, focus has centered on symptom description and reduc-
tion, rather than capturing QoL.
What are the alternatives?
Inquiries into the most fit-for-purpose PROMs for CFS/
ME were not forthcoming.57 CFS/ME-specific measures 
showed limited evidence of practical application, consis-
tency, or score interpretation. Despite Peters et al59 stressing 
the multifarious nature of LTCs, narrow symptom domains 
in single trials were found and samples were modest.24 The 
literature review revealed extremely limited evidence of 
QoL-research design or reliable practice monitoring in CFS/
ME.12,30 The full SF36 was the most prevalent measure, with 
well-corroborated design that addresses a range of categories, 
although regarded more of a health status questionnaire.35 Of 
the 36 questions, 14 relate to physical capability, ten entries 
record limitation to physical function, and four changes to 
physical role. The severity and disruption caused by pain is 
reviewed by two entries, and five points focus on health per-
ception. Only two questions capture the extent and frequency 
of health problems disrupting social activity, but eight entries 
aim to assess mood, with three relating to emotional impact 
on activity. A general health description and comparison to 
others uses five questions.
Of the publications focusing on QoL, there was a com-
bination of measuring physical function, psychological 
distress, and well-being. They concluded with powerful 
results that CFS has a pervasive negative impact.60 Hvidberg 
et al61 echoed this finding through application of the EQ5D. 
Nonetheless, the author regards this measure as too gener-
ally defined. Taylor62 and Taylor et al’s63 work on QoL and 
 well-being themes in CFS/ME were collated through the 
Frisch Quality of Life Inventory for LTCs.64 Valuable insights 
were gained through accounts of the measure, but the tool was 
not readily available. Query and Taylor65 demonstrated posi-
tive change through goal attainment, a good tool with which 
to report the effects of therapy, but the scale was restricted to 
a linear one-item domain. Haywood et al’s systematic review57 
confirmed that well-validated generic PROMs are applied in 
CFS/ME research and practice, but exhibit wide variation 
and lack sensitivity. They also revealed minimal assessment 
of measures’ applicability to the condition. Nevertheless, the 
review reinforced the belief that capturing changes in QoL 
as a measure of progress is essential.
It fell to van Heck and Vries’s66 comparative study of QoL 
in healthy volunteers and those with CFS/ME to introduce 
the World Health Organization’s QoL instrument (WHOQoL) 
and specifically the brief version (Bref26).67,68 Despite being 
a further generic tool and one that left Schoofs et al69 with 
unanswered questions, there was applicability to the condi-
tion. Devised around the same time as the full SF36 and now 
revised to 26 items, the WHOQoL-Bref26 contains all the 
categories recommended by the BACME, with better clarity 
between emotional distress and self-esteem.35 General health 
self-assessment and sexual function are new concepts, while 
requesting perceptions of satisfaction with work capability, 
safety, and leisure pursuits gives greater insight. Energy is 
considered separately to sleep quality, and fatigue is not rated 
against prescriptive activities.
Skevington and McCrate’s review of 27 disease groups 
and healthy controls with over 4,600 participants applied the 
WHOQoL-Bref26 to CFS/ME.68 A valid comparison to the 
SF36 was demonstrated, distinct QoL profiles gained, and 
greater sensitivity to change recorded. The Bref26 employs 
closed questions that gather quantitative responses, grouped 
into four domains. There are seven physical, six psycho-
logical, three social, and eight environmental descriptors to 
complete. QoL and health status are measured independently 
of the domains, with each question scoring 1–5. Skevington 
and McCrate68 report completion times ranged from 2–240 
minutes, with an average 20 minutes per patient. Only 3% 
required assistance in their study. The findings demonstrated 
acceptability and feasibility of use.
Discussion
Demographics
The demographic questions found in the first section of the 
WHOQoL-Bref26 are relevant to the UK setting. In the 
clinical setting, CFS/ME prevalence is high in age-groups 
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spanning between 20 and 50 years, with the majority having 
high academic background and professional occupation, as 
confirmed by Collin et al.70 As emphasized by Arroll and 
Senior,71 capturing such measurements is essential to tailoring 
clinical care. Identifying the right “at-risk” groups also pro-
motes targeted primary-care promotion and protection advice 
and equips all parties to recognize signs and symptoms.61
Symptoms
As a generic questionnaire, the WHOQoL-Bref26 does not 
record a category of symptoms, as demonstrated in the criteria 
required for diagnosis.12 Rather, this information is obtained 
initially from GP opinions at referral (Table 2). However, it 
is not until one-to-one assessment several months into the 
therapy program that a comprehensive personal account is 
taken. The author agrees with Arroll and Senior71 that such 
information can act as a concise and accurate checklist and 
be a welcome addition to PROMs. Without this perspective 
change, function and satisfaction with life and health may 
be considered in isolation. Jason et al20 emphasize the need 
for a more unified case definition.
Severity
NICE guidelines attribute a scale of severity to the condition 
that is applied at diagnosis: from mild to very severe. For 
most patients, their diagnosis is confirmed from the review 
of a completed referral that shows a clear correlation with 
the criteria.12 As this information is provided from the GP’s 
perspective, there can be inconsistencies. It is the one-to-one 
assessment that provides a detailed account, directed by the 
skilled specialist, but recounted by the patient. Accompanied 
by completion of a second set of PROMs, a comparison of 
symptoms and severity cannot be fully accurate. Dancey and 
Friend27 stressed the importance of capturing the effects of 
illness intrusiveness, and Arroll and Senior71 suggested offer-
ing more symptomatology descriptors and a rating from low 
to high severity, as outlined in the UK guideline.6 The PROM 
under consideration goes some way toward rating the severity 
of symptoms through functional and lifestyle limitation on 
a 5-point Likert scale.72
Phenotypes
As highlighted by Jonsjö et al,73 there remains ambiguity 
regarding a diagnosis of CFS/ME as one disease. The pre-
sentation of heterogeneous symptoms indicates important 
differences, as does the wide variation in daily functioning. 
Subgroups of symptoms seem plausible, and identifying 
phenotypes or profiles may explain differences, while antici-
pating the impact of symptoms on function.69,70,72 White et al25 
believed CFS/ME was an illness in which physiological and 
psychological factors interacted to cause and maintain dys-
function. The WHOQoL-Bref26 allows a distinguishing of 
presentations as defined by the patient, with a question asking 
whether the respondent considers themselves ill. The results 
can then be related to the primary reporting problem, demon-
strating differing combinations of experienced symptoms and 
disabilities. Arroll and Senior70 also suggested mood, fatigue, 
postexertion malaise, and neurological and gastrointestinal 
to be relevant classifications of further distinction.
Complex comorbidities
Hvidberg et al61 observed that in addition to CFS/ME, those 
with the condition frequently report an average of up to 
three other chronic illnesses. The author has found that due 
to complex comorbidities, some presentations have reduced 
capacity for improvement, as Skevington and McCrate68 also 
demonstrated. In contrast, those outlining a singular diagnosis 
of CFS/ME demonstrate higher scores in QoL, health status, 
function, and circumstances, according to the author’s obser-
vations. The opportunity to document the  illness experience in 
free text on the WHOQoL-Bref26 is thus a valuable indicator.
Table 2 UK NICE definition of CFS
Guidelines for evaluation and diagnosis
Fatigue with the following symptoms:
•	 new or had a specific onset (ie, not lifelong)
•	 persistent and/or recurrent
•	 unexplained by other conditions
•	 has resulted in substantial reduction in activity level characterized by 
postexertion malaise and/or fatigue (typically delayed, eg, by at least 
24 hours, with slow recovery over several days)
and one or more of the following symptoms:
•	 difficulty with sleeping, such as insomnia, hypersomnia, unrefreshing 
sleep, disturbed sleep–wake cycle
•	muscle and/or joint pain that is multisite and without evidence of 
inflammation
•	 headaches
•	 painful lymph nodes without pathological enlargement
•	 sore throat
•	 cognitive dysfunction, such as difficulty thinking, inability to 
concentrate, impairment of short-term memory, and difficulties with 
word finding, planning/organizing thoughts, and information processing
•	 physical or mental exertion or flu-like symptoms
•	 dizziness and/or nausea
•	 palpitations in the absence of identified cardiac pathology
The symptoms of CFS/ME fluctuate in severity, and may change in nature 
over time.
Notes: Reproduced with permission from © NICE (2007) CG53 Chronic 
fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and 
management.8 Available from www.nice.org.uk/guidance/cg53. All rights reserved. 
Subject to Notice of rights NICE guidance is prepared for the National Health 
Service in England. All NICE guidance is subject to regular review and may be 
updated or withdrawn. NICE accepts no responsibility for the use of its content in 
this product/publication. 
Abbreviations: CFS, chronic fatigue syndrome; ME, myalgic encephalomyelitis; 
NICE, National Institute of Health and Care Excellence.
Patient Related Outcome Measures 2018:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
258
Roberts
Functional classification
The WHOQoL-Bref26 allocates seven questions to the 
first domain, the physical component of the questionnaire. 
They include pain, mobility, sleep, and the ability to carry 
out activities of daily living. Energy levels are also noted, 
a classic symptom of the condition. However, the need for 
medical treatment to function and capacity to work are broad 
inquiries and more multifaceted than the WHOQoL-Bref26 
assumes. It is important to consider the complexities of CFS/
ME, which is frequently regarded as more globally disabling 
than many other conditions.6,42 
Domain two contains psychological descriptors such as 
enjoyment and meaning in life. How accepting the participant 
is of their body image and satisfaction with self are elements 
of QoL frequently very compromised in CFS/ME, due to 
physical limitations and mood.8 Only one question aims to 
capture anxiety and depression, but the assessment process 
undertaken at the service measures risk in depth. The author 
questions the categorizing of concentration as psychologi-
cal, which the CFS specialist professionals would reclassify, 
regarding cognitive difficulties as physical and related to 
sleep disorder.3 The author would also advocate for a question 
related to memory, as this cognitive function is frequently 
compromised.22 Nijs et al46 concurred that the experience of 
such symptoms is not psychological in effect. 
Social inquiry is relatively limited in domain three of the 
WHOQoL-Bref26, with only three questions allocated. This 
contrasts sharply to responses patients give as they describe 
the isolation, lack of understanding, and loss of relationships 
that come with social limitation.25 The final domain seeks to 
gain insight into environment impact. Here, opinion is sought 
on the health and safety of the physical environment, as well 
as asking about conditions of living space. Financial provision 
and the availability of information are grouped with access 
to health services and transport availability. Leisure also falls 
into this category, although the author would highlight the 
large overlap with social satisfaction.69
QoL
QoL can be defined as an individuals’ perceptions of their life 
situation, related to culture, goals, and the value system they 
subscribe to.66 When measuring aspects such as QoL, Nacul et 
al50 suggested that generic measures (unlike disease-specific 
tools) can make more accurate comparisons to healthy 
individuals, as demonstrated by Skevington and McCrate68 
in studying a range of other diseases. The first question 
measures QoL, which Dancey and Friend27 stressed is exten-
sively affected in CFS/ME, permeating all valued aspects of 
lifestyle, activity, and interests. The application of the SF36 
and EQ5D can provide only limited insight of the associated 
loss.49 Low QoL is distinct in CFS/ME, according to Collin 
et al,70 although this finding was disputed by Jonsjö et al.73 
Nonetheless, Skevington and McCrate68 compared 27 health 
conditions, reporting distinct QoL profiles among them.
Health status
The term “health status” refers to medical conditions and 
experiences of both disability and health care service encoun-
ters.66 As disability in CFS/ME is reportedly multidimen-
sional, Lowry et al60 stressed the importance of measures of 
functional status and well-being, to characterize health status; 
this is the second question in the WHOQoL-Bref and also 
a stand-alone score. Skevington and McCrate68 emphasized 
that personal beliefs and health expectations were integral 
to assessing QoL, due to their reciprocal influence. The 
questionnaire goes on to broadly assess how physical and 
psychological health, independence, and social contact form 
complex relationships.66,67
Pain
Arroll and Senior71 highlighted predominant-symptom sub-
groups of pain or fibromyalgia-like symptoms, a condition 
with many overlapping symptoms and treatments.74 Many 
of the patients treated at the author’s center have a dual 
diagnosis, which does not cause therapeutic conflict. The 
questionnaire reviews the impact of pain on QoL, but asks 
whether the sensations stop what the informant needs to do, 
rather than what they would want to do, which may produce 
different results. Nijhof et al75 observed that pain is disabling 
in CFS/ME, affecting both physical and social functioning. 
The author can confirm from clinical experience that such 
symptoms can be as severe as physical and cognitive fatigue, 
influencing all aspects of QoL and rates of improvement.
Work and interests
The impact of CFS/ME results in disruptions to productivity 
and meaningful occupation, which is often not the case with 
other conditions.25 Many are forced to give up work and 
interests, due to both physical and cognitive demands that 
cannot be sustained. As the workplace for many provides 
friendship, belonging, and identity, and significant loss and 
reduced self-worth is experienced.26 Greater understanding 
of these issues helps to dispel the misconception that CFS/
ME patients are malingerers.15 Nonetheless, modest atten-
tion is given in the WHOQoL-Bref26, with question 18 cap-
turing satisfaction with capacity to work. Inquires related 
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to the physical environment, money, and leisure could also 
be seen to make tentative links to difficulties that have 
wide-reaching consequences.6 Taylor et al63 highlighted an 
interrelationship with fear of exacerbation of symptoms, 
having too little energy to engage in physical exertion, 
creating a negatively influencing cycle on social interac-
tion and work capability. Nevertheless, quantifying what 
reduces isolation and increases understanding and support 
through the WHOQoL-Bref26 alone may be challenging. 
Specialist-clinic group programs, education of supporters, 
and (of equal influence) improvement in physiology and 
symptoms, gained through management strategies, are all 
influencing factors.
Relationships
A further explanation of reduction in satisfaction with 
significant relationships was offered by Nacul et al,50 who 
highlighted the emotional impact of the condition on carers 
and supporters. Relationships suffer, as fatigue prevents 
social contact and intimacy.68 The WHOQoL-Bref26 offers 
only three inquiries related to relationships and support. It 
does, nevertheless, offer clarity of just how limited interac-
tion becomes by asking about sexual intimacy. The author 
reports that the inclusion of this question can cause a negative 
reaction for some respondents, who leave it blank or suggest 
this is not for discussion. This theme is echoed in sessions 
when an apology is often issued before approaching the issue 
with the therapist. This is a significant indicator of disability 
influencing QoL frequently neglected.
Self-efficacy
The NICE-led rehabilitation approach delivered in the service 
in question aims to build self-efficacy through education and 
support.8 Defined as confidence in executing actions and 
managing a wide array of situations, improvement in such 
abilities frequently correlates with treatment progression. 
This aspect of health status is not addressed directly in the 
WHOQoL-Bref26, with the closest inquiry coming from a 
question that asks how much the patient needs medical treat-
ment to function. This is suggestive of change resulting from 
reduced physical symptoms, but could also be interpreted as 
measuring successful self-management and independence. 
Question 13 asks whether the respondent has the information 
they need, and question 24 about access to health services. 
Both could be interpreted as related to self-efficacy, but are 
placed in the environmental domain, and are thus regarded 
as obtuse. Kennedy et al76 found that measuring progress in 
patients’ self-confidence is not straightforward.
Mood
Nacul et al50 were keen to point out that lack of energy may 
well not be the most disabling feature, as in addition to 
physical disability, CFS/ME has a significant reactive impact 
on mental health. Those describing being ill with a mood 
disorder are likely to score the lowest in all domains and 
exhibit the most modest change.67 Nacul et al50 agreed that 
the impact of symptoms reduced psychological well-being 
dramatically revealed in a higher rate of depression than 
comparative groups. Daniels et al77 discovered a 33%–42% 
prevalence of anxiety and depression with atypical presen-
tation. On first glance at the WHOQoL-Bref26, it appears 
that mood impact is gathered through a singular inquiry – 
question 26. Responses to the question of negative feelings, 
anxiety, low mood, and feeling “blue” are never, seldom, quite 
often, very often, and always. However, the comprehensive 
psychological domain asks about enjoyment, meaning, body 
image, and satisfaction with self, a rounded picture from 
which the therapist can tailor individualized treatment and 
without which difficulties will remain.76 As Dancey and 
Friend27 observed, the perception of not being taken seriously 
accounts in part for higher illness-worry scores, low mean-
ing in life, and depression in CFS/ME, a causal relationship 
associated with feeling delegitimized.76 The author identifies 
with the urgency to consider in depth the level and impact 
of emotional stress.28
Accuracy
The PROMs applied at the author’s center seek firstly to gain 
information on referral. One-to-one assessment to evaluate 
progress from group therapy provides a second opportunity 
and informs the individualized contact to come, on average 
8 months after initial acceptance. The final questionnaire 
reviews individualized therapy at discharge, which varies 
but can be up to a year later. Nevertheless, the earliest point 
of intervention has been observed to be when the condition 
is at its most fluctuating and the respondent most unrealistic 
about their limitations. Currently, the service utilizes only 
two of the originally recommended BACME MDS: the 
SF36 – physical function (eleven items)34 and Chalder Fatigue 
Questionnaire.30 Both place a large emphasis on the physical 
domain. The former is frequently inaccurate, as scores often 
diminish with acceptance and insight into the reality of the 
condition.48 The latter fails to interpret the physical lack of 
energy as a valid cause for reduced cognitive functioning. 
Neither emphasizes the impact and measurement of QoL. 
The existing measures risk greater inaccuracy than the 
WHOQoL-Bref26.
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Conclusion
The author suggests that the WHOQoL-Bref26 has the capac-
ity to record the demographics of CFS/ME populations60,69 
and to highlight how disabling CFS/ME can be from the 
patient’s perspective by showing the impact of the condition 
on important activities.58 Patients’ views and feelings should 
not be regarded as inadequate or an inappropriate basis for 
making important decisions.77 Capturing personal health 
perspectives relays what helps patients feel better and more 
able to achieve everyday functions. The WHOQoL-Bref26 
asks about the effect of the condition on QoL, rather than 
capabilities, and is applicable at any and multiple stages of 
therapy. The questionnaire has a less challenging format 
than other measures, as patients have influenced the design, 
rather than researchers. Respondents are able to report 
from their own context, capture beliefs, and communicate 
personal values and goals.66,67 The heterogeneity and impact 
of complex comorbidities are also accounted for.72 Wiering 
et al78 describe how patient-designed measures prove more 
acceptable and meet the challenges the CFS/ME patient group 
faced. These have a broader remit than the Chalder Fatigue 
Scale30 and can consider a wider range of impact.
LTCs have complex components, such as have been seen 
in the outline of CFS/ME, with comorbidities and the influ-
ence of depression and anxiety.2,76 The concise nature of the 
WHOQoL-Bref26 makes it suitable for application and use 
during professional–patient interaction and as a therapeu-
tic tool.40 Fluctuations due to circumstances and stressors 
influencing scores are difficult to account for.19,28 However, 
the WHO emphasizes that measurement must account for 
changes in the severity of the illness and also provide an 
estimate of well-being.67 Therefore, the WHOQoL-Bref26 
has the potential to evidence the quality of care outcomes.8 
PROMs data are subjective, and as Devlin and Appleby42 
described, purposefully so. Nevertheless, a reliable and well-
validated questionnaire is essential to produce quantitative 
data.58 The WHOQoL-Bref26 has the potential to fill the gap 
identified in CFS/ME practice and capture change delivered 
through therapeutic interventions,6 being less resource-
intensive and able to increase accuracy in reporting. Devlin 
and Appleby42 outlined the importance of measuring and 
benchmarking the performance of health care providers.
The WHOQoL-Bref26 offers but a small snapshot of ill-
ness presentation and progression, with severity and longevity 
being recorded elsewhere. Nacul et al50 argued that a lack 
of specificity of symptoms makes disease characterization 
and disability assessment challenging. Facility to include 
this information would expand understanding and  planning 
of tailored interventions. Nelson et al41 warned against 
clinicians believing they knew enough about their patients’ 
problems and only regarding measurement as additional to 
their workload. The author thus endorses further work with 
primary-care physicians. Stenhoff et al17 confirmed that the 
condition receives little attention in the medical curriculum. 
Patients continue to report a lengthy period to diagnosis, 
frequently experiencing blame, and being held accountable 
for their poor health.78 Devlin and Appleby42 stressed the 
relevance of disease-specific measures, but cautioned against 
relying on overall scores that lose the descriptive richness of 
accounts and unique experiences. Bayliss et al79 warned that 
a skeptical view remains wherein, without a lack of identifi-
able pathology in CFS/ME there is no real illness, and at best 
symptoms are purely somatic. The author intends to explore 
further alternatives that could prove able to measure with 
even greater sensitivity CFS/ME’s characteristically long 
and unpredictable course.24,65,67
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